About Heterogeneous nuclear ribonucleoprotein C-like 1
Heterogeneous nuclear ribonucleoprotein C-like 1 (HNRNPCL1) is a protein
from Homo sapiens identified by UniProt accession
O60812, 293 residues long.
MolForge cross-references it against 0 known binders and
18 disease associations.
Target properties
| Protein name | Heterogeneous nuclear ribonucleoprotein C-like 1 |
| UniProt accession | O60812 |
| Gene | HNRNPCL1 |
| Organism | Homo sapiens |
| Length | 293 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (18)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.43
- optic cup area measurement · score 0.16
- visual perception measurement · score 0.15
- Mayer-Rokitansky-Kuster-Hauser syndrome type 1 · score 0.12
- Mayer-Rokitansky-Kuster-Hauser syndrome · score 0.12
- MODY · score 0.05
- hereditary hyperferritinemia with congenital cataracts · score 0.04
- juvenile cataract-microcornea-renal glucosuria syndrome · score 0.04
- Juvenile cataract - microcornea - renal glucosuria · score 0.04
- islet cell adenomatosis · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O60812-F1 | alphafold | PREDICTED | 70.81 | — |
Amino-acid sequence (293 residues)
MASNVTNKMD PHSMNSRVFI GNLNTLVVKK SDVEAIFSKY GKIAGCSVHK GFAFVQYDKE KNARAAVAGE DGRMIASQVV DINLAAEPKV NRGNAGVKRS AAEMYGSSFD LDYGFQRDYY DGMYSFPARV PPPPPIALAV VPSKRQRLSG NTSRRGKSGF NSKSGKRGSS KSGKLKGDDL QAIKQELTQI KQKVDSLLEN LEKIEKEQSK QEVEVKNAKS EEEQSSSSMK KDETHVKMES EGGAEDSAEE GDPLDDDVNE DQGDDQLELI KDDEKEAEEG EDDRDSTNGQ DDS
Explore Heterogeneous nuclear ribonucleoprotein C-like 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets